The use of HER2-targeted therapies has dramatically improved the outcome and survival of HER2-expressing breast cancer patients over the last decades since the approval of the first HER2-targeted antibody, trastuzumab, in 1998 [5]. Here, ERBB2 is linked to breast carcinoma.